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1. Introduction
  Dendrimer represents a novel type of polymeric 
material. It is also known as starburst[1] or cascade[2] 
or molecular trees[3] or arborols, or polymers. They 
attract the increasing attention of all because of 
their unique structure, high degree of control over 
molecular weight and the shape that has led to the 
synthesis of unimolecular micelles[4]. Considering the 
use of dendrimers for drug delivery, it is necessary 
that they are nontoxic and biocompatible. However, it 
has been demonstrated that widely used dendrimers, 
such as PAMAM and poly (propylene imine) (PPI) 
dendrimers bearing primary amino group termini, 
are quite cytotoxic, and also these dendrimers were 
cleared rapidly from the circulation when administered 
intravenously[5]. 
   Poly ethylene glycol (PEG) is typically a clear, 
colorless odorless substance that is soluble in water, 
stable to heat, inert to many chemical agents, that does 
not hydrolyze or deteriorate, and is generally non-
toxic, PEG is considered to be biocompatible, which is 
to say that PEG is capable of coexistence with living 
tissue or organisms without causing harm, as reviewed 
earlier[6]. 
   It has been shown that covalent attachment of 
poly (ethylene glycol) to proteins decreases their 
immunogenicity and increases their circulation time[7]. 
Moreover, a number of studies have demonstrated 
that poly (ethylene glycol) chains grafted to surface 
of polymer micelles and liposomes suppress their 
interaction with plasma proteins and cells and prolong 
their blood elimination half-life[8]. 
   On the basis of these findings, it seems that 
dendrimers covered with poly (ethylene glycol) grafts 
are attractive compounds as drug carriers in in vivo. 
Such molecules are expected to encapsulate drugs in 
their dendrimer moiety and reveal biocompatibility 
due to their hydrophilic shell consisting of poly 
(ethylene glycol) grafts. The present study was aimed at 
developing and exploring the use of PEGylated newer 
EDA-PPI dendrimers for delivery of anti-bacterial 
drug, Trimethoprim. Trimethoprim was selected for 
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incorporation into PEGylated ethylenediamine (EDA)-
PPI dendrimers based on its antibacterial activity. 
PEGylation of EDA-PPI dendrimers establishes 
suitability of PEGylated dendrimer as a drug delivery 
system for Trimethoprim.
2. Materials and methods
2.1. Materials
   PEG4000, Reney Nickel (Sigma, Germany), Raney 
Nickel  ( Merck,  India ) ,  t r ie thylamine,  d ioxan, 
ethylenediamine, acrylonitrile (CDH, India), N, N 
dicyclohexyl carbodiimide (DCC), Cellulose dialysis bag 
(MWCO 12-14 Kda, Himedia, India), 4 dimethyl amino 
pyridine (sd-fine chemicals, India), Agar plates ( Hi 
media, Mumbai), Trimethoprim was a benevolent gift 
from Shasun Pharmaceuticals, Chennai, India.
2.2. Methods
2.2.1. Synthesis of 5.0 G EDA-PPI dendrimers
   
   EDA-PPI dendrimers were synthesized by the 
previously reported and established procedure. 
The half generation EDA-dendrimer-(CN)4n (where 
n is generation of reaction or reaction cycle) was 
synthesized by double Michael addiction reaction 
between acrylonitrile (2.5 molar times per terminal NH2 
group of core amine moiety) and aqueous solution of 
ethylenediamine or previous full generation dendrimers. 
After the initial exothermic phase, the reaction mixture 
was heated at 80  曟 for 1 h to complete the addiction 
reaction. The excess of acrylonitrile was then removed 
by vaccum distillation (16 mbar, bath temperature 40  曟
). 
   The full generation EDA-dendrimer-(NH2)4n was 
obtained by hydrogenation in methanol at 40 atm 
hydrogen pressures and 70  曟 for 1 h with Reney Nickel 
(pretreated with hydroxide and water) as catalyst. The 
reaction mixture was cooled, filtered and the solvent 
was evaporated under reduced pressure. The product 
was then dried under vacuum. EDA-PPI dendrimers 
up to 5.0 G were prepared by repetition of all the 
above steps consecutively, with increasing quantity of 
acrylonitrile.
2.2.2.  Synthesis  o f  PEGylated 5.0G EDA-PPI 
dendrimers
   
   To a solution of 5 G EDA-PPI dendrimer (0.01 mmol) in 
dimethyl sulfoxide (DMSO) (10 mL), PEG 2000 (0.32 mmol) 
in DMSO (10 mL) and N, N dicyclohexyl carbodiimide 
(DCC) (0.32 mmol) in DMSO (10 mL) were added and the 
solution was stirred for 5 days at room temperature. 
   The product was precipitated by addition of water, 
filtered and dialyzed (MWCO 12-14 Kda, Himedia, 
India) against double distilled water for 24 h to remove 
free PEG 2000, DCC and partially PEGylated dendrimers 
followed by lyophilization (Heto drywinner, Germany).
2.2.3. Drug loading in formulation
   
   The known molar concentrations of EDA-PPI 
dendrimer and PEGylated 5.0 G dendrimers were 
dissolved separately in methanol and mixed with 
methanolic solution of trimethoprim (100 mol). 
   The mixed solutions were incubated with slow 
magnetic stirring (50 rpm) using teflon beads for 24 
h. These solutions were twice dialyzed in cellulose 
dialysis bag (MWCO 1000 Da Sigma, Germany) against 
double distilled water under sink conditions for 10 min 
to remove free drug from the formulations, which was 
then estimated spectrophotometrically (λmax 229nm) 
(UV-1601, Shimadzu, Japan) to determine indirectly the 
amount of drug loaded within the system. The dialyzed 
formulations were lyophilized and used for further 
characterization.
2.2.4. Antibacterial assay
   
   About six Staphylococcus aureus, Bacillus subtilis, 
Enterococcus faecaulis, Escherichia coli, Pseudomonas 
aeruginosa and Klebsie l la  pneumoniae  human 
pathogenic bacterial strains were used. All six strains 
were tested against Trimethoprim loaded dendrimer. 
The antimicrobial activity of Trimethoprim loaded 
dendrimer was determined by agar well diffusion 
method against different bacteria as described. In 
this method, pure isolate of each bacterium was 
sub-cultured in nutrient broth at 37 曟 for 24 h. 
   One hundred microlitres (about 106 CFU/mL, 
standardized by 0.5 Mac-Farland) of  each test 
bacterium was spread with the help of sterile spreader 
on to a sterile Muller-Hinton Agar plate  so as to 
achieve a confluent growth. The plates were allowed 
to dry and a sterile cork borer of diameter 6.0 mm was 
used to bore wells in the agar plates. Subsequently, 
a 50 毺L volume of the dendrimer, pure Trimethoprim 
and drug loaded dendrimer was introduced in triplicate 
wells into Muller-Hinton agar plate. 
    The plates were allowed to stand for 1h or more for 
diffusion to take place and then incubated at 37 曟 for 
24 h. The zone of inhibition was recorded to the nearest 
size in mm[9].
2.2.5. Statistical analysis 
   
   Results were analysed by mean ± SD and it was 
calculated by ANOVA followed by Dunnet’s test. 
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P<0.000 1 were considered as significant 
3. Result
   The polypropyleneimine dendrimer was synthesized 
by using ethylenediamine as a core. The synthesized 
dendrimer were further PEGylated with PEG2000. 
The PEGylated dendrimer is used as carrier system 
in  which  Tr imethopr im was  loaded  and  drug 
entrapment efficiency was calculated as 60.20±0.03. 
The antibacterial activity of drug loaded dendrimer 
was performed by agar well diffusion method. The 
results are compared with plain dendrimer and pure 
Trimethoprim and thus, it reveals that the PEGylated 
drug loaded dendrimer shows potent activity than that of 
plain dendrimer on both the selected organisms (Table 
1). Further, it was observed that the Trimethoprim does 
not show inhibitory zone against Klebsiella pneumoniae. 
Hence it clarifies that the selected organisms are 
resistant to Trimethoprim. Thus, the synthesized 
PEGylated polypropyleneimine dendrimer is an effective 
carrier to target any antibacterial agent for resistant 
producing organism. 
4. Discussion
   From the present study it can be concluded that the 
prepared Trimethoprim loaded PPI dendrimer were 
highly effective against resistant producing organisms. 
However the synthesized system was found to be 
suitable and safe to deliver any drug to the targeting 
sites.
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Table 1
Zone of inhibition of trimethoprim loaded PPI dendrimer.
Treatment S taphy lococcu s 
aureus      
Bacillus subtilis E n t e r o c o c c u s 
faecaulis 
Escherichia coli        P s e u d o m o n a s 
aeruginosa 
Klebsiella pneumon
iae                                  
DMSO NA NA NA NA NA NA
Plain PPI dendrimer 26.00依2.65* 25.60依1.52* 25.30依2.08* 26.30依1.52* 26.33依3.21* 24.30依3.05*
Trimethoprim NA NA NA NA NA 19.60依0.57*
DLDT(50 毺g/mL) 13.30依2.08 11.30依1.52* 11.00依1.73 13.30依1.52* 12.30依1.52* 13.60依2.34
DLDT(100 毺g/mL) 16.60依1.52* 20.30依0.57* 15.30依2.08* 16.60依0.57* 15.60依4.93 18.00依3.60
*: P<0.000 1. NA - No activity; PPI - Polypropyleneimine dendrimer; DLDT - Drug loaded dendrimer; DMSO- Dimethyl sulphoxide (n=3).
